Lyon, France, may 30, 2017 POXEL SA (Euronext POXEL – FR0012432516), a biopharmaceutical company specializing in the development of innovative treatments against metabolic diseases, including type 2 diabetes, today announced that an abstract on the Imeglimine has been accepted for presentation by poster at the 77th Congress of the American Diabetes Association (ADA), which will be held from 9 to 13 June 2017 at the San Diego Convention Center in San Diego, California, United States.
Download the free guide
Boost your gains
Information regarding the poster on the Imeglimine
Poster n° 2054-P
Title : “Imeglimin Protects from Diabetic Cardiomyopathy in the Obese Zucker Rat”
Session name : Category 22-Obesity-Animal
Date, time & place : June 11, 2017, 12: 00 to 13: 00, Poster Hall, San Diego Convention Center
Poxel will announce the results by way of a press release after the presentation.
About the Imeglimine
The first representative of a new chemical class of oral agents, the Glimines. The Imeglimine acts on three main target organs involved in glucose homeostasis : the liver, muscles and pancreas. The Imeglimine has a unique mechanism of action which targets the mitochondrial bioenergetics. The result is a potential effect in reducing blood sugar levels, as well as the potential to prevent endothelial dysfunction, which may have protective effects against the micro-and macrovascular complications induced by diabetes, and the benefits of the protection and beta-cell function, which may slow down the progress of the disease. This mode of action distinct from that of existing treatments for type 2 diabetes because of the Imeglimine a candidate of choice as monotherapy and as an adjunct to other treatments such as metformin, or sitagliptin.
About Poxel – www.poxel.com
Poxel is based on its level of development expertise in metabolism to develop and enhance a portfolio of drug candidates, currently focused on type 2 diabetes. We have completed the development of phase 2 in the United States and Europe our product is the most advanced, the Imeglimine, the first of a new class of therapeutic targeting of the mitochondrial dysfunction, and which entered into clinical development to phase 2b in japanese patients. We are continuing the development of our 2nd program, the PXL770, an activator direct AMPK. We intend to generate growth through strategic partnerships and the development of our portfolio.
Download the free guide
Boost your gains
